186 related articles for article (PubMed ID: 35935979)
1. A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma.
Chen B; Yao Y; Mao D; Li C; Wang X; Sheng S; Zhang L; Wang X; Chen S; Xu W; Deng J; Sun C; Zhou Q; Lowe S; Bentley R; Shao W; Li H
Front Immunol; 2022; 13():928742. PubMed ID: 35935979
[TBL] [Abstract][Full Text] [Related]
2. Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma.
Zhou R; Peng N; Li W
Front Immunol; 2022; 13():964919. PubMed ID: 36059494
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
Han C; Zhang C; Wang H; Li K; Zhao L
BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
[TBL] [Abstract][Full Text] [Related]
4. A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma.
Hua X; Ge S; Zhang J; Xiao H; Tai S; Yang C; Zhang L; Liang C
Cell Death Discov; 2021 Sep; 7(1):252. PubMed ID: 34537809
[TBL] [Abstract][Full Text] [Related]
5. Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes frofiling.
Liu C; Tao Y; Lin H; Lou X; Wu S; Chen L
Front Mol Biosci; 2022; 9():962435. PubMed ID: 36090054
[No Abstract] [Full Text] [Related]
6. A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma.
Ye Z; Zheng M; Zeng Y; Wei S; Huang H; Wang Y; Liu Q; Lin Z; Chen S; Zheng Q; Chen L
Front Oncol; 2021; 11():612952. PubMed ID: 34235071
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
Front Immunol; 2022; 13():854785. PubMed ID: 35392086
[TBL] [Abstract][Full Text] [Related]
8. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer.
Huang W; Su D; Liao X; Yang T; Lu Y; Zhang Z
Sci Rep; 2023 Jan; 13(1):789. PubMed ID: 36646765
[TBL] [Abstract][Full Text] [Related]
9. Development of a prognostic metabolic signature in stomach adenocarcinoma.
Gong Y; Wu S; Dong S; Chen S; Cai G; Bao K; Yang H; Jiao Y
Clin Transl Oncol; 2022 Aug; 24(8):1615-1630. PubMed ID: 35355155
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma.
Lin G; Yang Y; Feng Q; Zhan F; Sun C; Niu Y; Li G
Immunogenetics; 2022 Jun; 74(3):285-301. PubMed ID: 35119508
[TBL] [Abstract][Full Text] [Related]
11. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.
Wu Y; Ren L; Tang Y; Zhu Z; Liu S; Jiang Y; Zhang S; Zhuang X; Chen Y
Aging (Albany NY); 2023 Oct; 15(20):11588-11610. PubMed ID: 37889539
[TBL] [Abstract][Full Text] [Related]
12. Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma.
Wang Y; Zhang X; Dai X; He D
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1161-1170. PubMed ID: 34319826
[No Abstract] [Full Text] [Related]
13. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract][Full Text] [Related]
14. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.
Yuan Q; Zhou Q; Ren J; Wang G; Yin C; Shang D; Xia S
Cancer Med; 2021 Jun; 10(12):4004-4016. PubMed ID: 33982398
[TBL] [Abstract][Full Text] [Related]
15. Identification of a 14-lncRNA Signature and Construction of a Prognostic Nomogram Predicting Overall Survival of Gastric Cancer.
Nie K; Deng Z; Zheng Z; Wen Y; Pan J; Jiang X; Yan Y; Liu P; Liu F; Li P
DNA Cell Biol; 2020 Sep; 39(9):1532-1544. PubMed ID: 32644844
[TBL] [Abstract][Full Text] [Related]
16. Establishment of the molecular subtypes and a risk model for stomach adenocarcinoma based on genes related to reactive oxygen species.
Li G; Ping M; Zhang W; Wang Y; Zhang Z; Su Z
Heliyon; 2024 Mar; 10(5):e27079. PubMed ID: 38463816
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of the Prognostic Significance of Hsa-miR-100-5p and Its Related Gene Signature in Stomach Adenocarcinoma.
Wang G; Yang L; Hu M; Hu R; Wang Y; Chen B; Jiang X; Cui R
Front Cell Dev Biol; 2021; 9():736274. PubMed ID: 34604236
[TBL] [Abstract][Full Text] [Related]
18. A novel microRNA signature predicts survival in stomach adenocarcinoma.
Ding B; Gao X; Li H; Liu L; Hao X
Oncotarget; 2017 Apr; 8(17):28144-28153. PubMed ID: 28423653
[TBL] [Abstract][Full Text] [Related]
19. Identification of mitochondrial respiratory chain signature for predicting prognosis and immunotherapy response in stomach adenocarcinoma.
Yang J; Jin F; Li H; Shen Y; Shi W; Wang L; Zhong L; Wu G; Wu Q; Li Y
Cancer Cell Int; 2023 Apr; 23(1):69. PubMed ID: 37062830
[TBL] [Abstract][Full Text] [Related]
20. A Five-gene Signature Based on MicroRNA for Predicting Prognosis and Immunotherapy in Stomach Adenocarcinoma.
Wang T; Chen P; Li T; Li J; Zhao D; Meng F; Zhao Y; Zheng Z; Liu X
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38310388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
